Amgen's Dazodalibep Competitive Profile Still 'Open Question': Citi

Citi analysts say that Amgen's dazodalibep treatment is still an 'open question' in terms of its competitive profile.

This view is based on backtested results, which are not a guarantee of future actual results. The results reflect the performance of a strategy not historically offered to investors and do not represent returns that any investor actually attained.

The analysts warn that changes in assumptions may have a material impact on the backtested returns presented. They also note that certain assumptions were made for modeling purposes and are unlikely to be realized.